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Abstract
A previous study indicated that the coadministration of decoction of Citri Grandis Pericarpium (CGP), the peels of Citrus grandis
(Rutaceae), significantly increased the blood level of cyclosporin (CsA) and resulted in acute intoxication of pigs. In this study, we
aimed to measure the effects of CGP on the distribution of CsA in both lymphoid and non-lymphoid tissues as well as on the immune
cell function in mice. Our results showed that coadministration of 3 g/kg CGP with CsA (Neoral®, 10 mg/kg) significantly decreased
the concentrations of CsA in blood, liver, kidney and spleen by 37 %, 45 %, 46 % and 51 %, respectively, after a two week treatment.
The decrease in CsA level correlated positively with the CGP dose. Pharmadynamically, coadministration of CGP restored the phagocytosis activity in blood decreased by CsA. Moreover, the nitric oxide production of activated macrophages and helper T cell type 1
(Th1) cytokines production suppressed by CsA were also reversed by the coadministration of CGP. In conclusion, coadministration of
CGP significantly decreased the systemic exposure of CsA and resulted in higher macrophage and Th1 type activities than giving CsA
alone in mice. Therefore, the combined use of CGP with CsA requires close monitoring clinically.
Key words: Citrus grandis, cyclosporin, immune response, Th1/Th2 cytokines

Introduction
Cyclosporin (CsA), a lipophilic cyclic peptide isolated
from the fungus Hypocladium inflatum gams(1), is a potent
immunosuppressant that is widely used for the treatment
of autoimmune diseases and allograft rejection (2,3) . It
is well known that CsA binds to cyclophilin to form an
active complex which inhibits the enzyme calcineurin
phosphatase (4) . Without the dephosphorylation by
calcineurin, NFAT (nuclear factor of activated T cells)
family members are unable to translocate into the nucleus
to activate cytokine genes in T cells to result in the
suppression of immune responses(5,6). In addition, CsA has
been recently found to block the p38 and JNK signaling
pathways triggered by antigen recognition in T cells(5).
The therapeutic window of CsA is very narrow (7).
CsA and its metabolites have been reported to exert
many side effects, such as nephrotoxicity, hepatotoxicity,
neurotoxicity, and systemic hypertension(8,9). Therefore,
therapeutic drug monitoring of CsA is essential for
clinical application. In addition, CsA is a substrate for
both CYP3A4 and P-glycoprotein (P-gp), a drug efflux
transporter. Numerous drugs such as diltiazem (10) ,
ketoconazole (11) and nefazodone (12) have been reported
to interact with CsA by altering the CYP3A4 metabolic
pathway or affecting P-gp function in both liver and
intestine mucosa(12-14).
* Author for correspondence. Tel: +886-4-22053366 ext. 8519;
Fax: +886-4-22053764; E-mail: shfang@mail.cmu.edu.tw

In recent decades, many immunosuppressive drugs
have been prescribed to prevent allograft rejection and
their mechanisms were found to inhibit the expression of
IL-2, to suppress the immune responses mediated by B
lymphocytes, to exert anti-inflammatory effect, to induce
the apoptosis of activated T lymphocytes as well as to
block the p38 and JNK signaling pathways (15). On the
other hand, natural flavonoids were recently reported to
exhibit a variety of beneficial pharmacological properties,
including antioxidation, antiviral, and anti-inflammatory
activities(16). Therefore, people are encouraged to ingest
flavonoid-rich diet. Flavonoids are the most abundant
polyphenols present in human diet such as fruits,
vegetables, tea and red wine. However, flavonoids were
reported to modulate CYP 3A4 and P-gp(17-19). Since CsA
is a substrate for both CYP3A4 and P-gp, the health risk
associated with high intake of flavonoid for those taking
CsA routinely is an important clinical issue.
Previous studies indicated that grapefruit juice
interacted with CsA pharmacokinetically, led to increased
CsA blood levels (20-22) and resulted in serious clinical
consequences. Citri Grandis Pericarpium (CGP), the peels
of Citrus grandis (Rutaceae), is a Chinese herb containing
flavonoid constituents such as naringin and naringenin
like grapefruit(23). We hypothesized that CsA was subject
to clinically relevant interaction with CGP decoction
as with grapefruit juice. An earlier study indicated
that the coadministration of decoction of Citri Grandis
Pericarpium (CGP), the peels of Citrus grandis (Rutaceae),
significantly increased the blood level of cyclosporin (CsA)
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and resulted in acute intoxication of pigs(24). Furthermore,
because CGP contains antioxidant flavonoids which may
exert pharmacological activities on immune systems, the
present study aimed to investigate the pharmacokinetic and
pharmacodynamic interactions of CGP with CsA through
measuring CsA tissue distribution and related immune
responses in mice.

Materials and methods
I. Mice
Balb/c mice were purchased from National Laboratory
Animal Center (Taipei, Taiwan) and maintained in the
Animal Center of China Medical University. The animal
room was at a 12-hr light and dark cycle with constant
temperature and humidity. All mice used were 8 weeks
old. All procedures were performed according to the Guide
for the Care and Use of Laboratory Animals (NRC, USA).
II. Drugs
Cyclosporin (Neoral ® , 100 mg/mL) was provided
by Novartis (Taiwan) Co. Ltd. Lipopolysaccharide
(LPS), Concanavalin A (ConA) and Phosphate buffered
saline (PBS) were purchased from Sigma Chemical (St.
Louis, MO, USA). Recombinant interferon-γ (IFN-γ)
was purchased from PeproTech (Margravine, London,
England). The spleen cells and peritoneal excluded
macrophages were maintained in the RPMI-1640 medium
supplemented with 10% fetal calf serum (FCS), 1%
penicillin, 1% streptomycin, and 200 mM L-glutamine
(Gibco BRL, Grand Island, NY, USA).
III. CGP Decoction Preparation and Quantitation of
Flavonoids
The crude drug of CGP was purchased from an herbal
store in Taichung. Four liters of water were added to 200
g of sample and heating was carried out on a gas stove.
After boiling, gentle heating was continued for about 2 hr
until the volume reduced to less than half of the original
volume. The mixture was filtered while hot and sufficient
hot water was added to make 2 L, which was frozen at
-20°C for later use. For the quantitation of flavonoids, CGP
decoction (300 μL) was added with 700 μL of methanol.
After centrifugation, the supernatant was added with equal
volume of methanol containing 6,7-dimethoxycourmarin
as the internal standard and then subjected to HPLC
analysis. The HPLC apparatus included two pumps (LC10AL, Shimadzu, Japan) and an UV spectrophotometric
detector (SPD-10A, Shimadzu, Japan). The RP-18
column (LiChrospher ® , 4.0 × 250 mm) was equipped
with a prefilter. The mobile phase was acetonitrile and
0.1% ortho-phosphoric acid (22:78) and the flow rate was
1.0 mL·min-1 with the detection wavelength set at 288 nm.

Quantitation results showed that the dissolved amounts
of naringin and naringenin into the decoction from CGP
crude drug were 1.7 ± 0.1 mg·g-1 and 20.5 ± 0.3 μg·g-1,
respectively.
IV. Animals and Drug Administration
Mice were randomly divided into A~H groups. Each
group included eight mice. Group A was the control and
was given equivalent amount of water. Groups B~E were
given a dose of 10 mg/kg cyclosporin (Neoral®, diluted
with olive oil) with CGP at daily doses of 0, 1, 2 and 3
g/kg, respectively. CGP was given right before CsA. The
drugs were administered via gastric gavage. Groups F~H
were given CGP alone at 1, 2 and 3 g/kg, respectively.
V. Determination of Cyclosporin Concentration in Blood,
Liver, Kidney, and Spleen
After dosing different combinations of CsA and CGP
to the mice for two weeks, the concentrations of CsA in
blood and various tissues were measured(25). Mice were
anesthetized with intramuscular injection of ketamine (20
mg/kg) and then blood sample (100 μL) was withdrawn
from the retro-orbital venous plexus. Spleen cells (1 ×
10 7 ) and 100 mg of liver or kidney were individually
homogenized in 100 μL of PBS. The CsA concentration
was measured by employing a specific monoclonal
fluorescence polarization immunoassay (26) using a CsA
kit (Abbott, Abbott Park, IL, USA). The assay was
calibrated for concentrations ranging from 25.0 to 1500.0
ng/mL. The LLOQ (lower limit of quantitation) of this
assay is 25.0 ng/mL. The accuracy of this method was
further assessed with recovery studies by spiking CsA
into homogenates of spleen, liver, kidney and water
in triplicates to afford 100.0, 200.0 and 500.0 ng/mL.
Afterwards, the concentrations obtained in various tissues
with the corresponding ones in water were compared.
VI. Quantification of Phagocyte Activity
Blood sample was withdrawn from the retro-orbital
venous plexus after dosing CsA and CGP to mice for two
weeks. The quantitative analysis of phagocyte activity
was performed using a Phagotest ® kit (ORPEGEN
Pharma, Heidelberg, FRG) following the manufacturer’s
instruction(27). Briefly, heparinized whole blood (100 μL)
was incubated with the fluorescein isothiocyanate (FITC)labelled E. coli (50 μL) at 37°C and a negative control
sample remained on ice. The phagocytosis is stopped by
placing the sample on ice and adding quenching solution
to quench the FITC fluorescence of surface bound bacteria,
leaving the fluorescence of internalized particles unaltered.
After washing, the percentages of phagocytes that had
ingested bacteria and the activities (the number of bacteria
per cell) were monitored using a FACscan flow cytometer
(Becton Dickinson). Data analysis was performed using
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the Cell Quest Software (Becton Dickinson, San Diego,
CA) and calculated by (the percentage of phagocytes
which have ingested FITC-labeled E. coli at 37°C) minus
(the percentage of phagocytes which have ingested FITClabeled E. coli bacteria on ice).
VII. Determination of Cell Populations in Splenocytes
Surface staining was performed as described
above (28) . Spleen cells (1 × 10 6 ) were incubated with
fluorescein isothiocyanate [FITC]-conjugated anti-CD3
(Leinco Technologies, Inc., St. Louis, MO, USA), and
phycoerythrin [PE]-conjugated anti-CD4, or [FITC]anti-CD3 and [PE]-anti-CD8, or [FITC]-anti-CD3 and
[PE]-anti-CD19 (PharMingen, San Diego, CA, USA),
respectively, at 4°C for 30 min. The cells were washed
twice, suspended in 0.5 mL of PBS and subjected
to FACScan analysis. A total of 10,000 cells were
counted and the frequency of each cell surface marker
was determined using appropriate software. The flow
cytometry was regularly calibrated with CaliBRITE beads
(Becton Dickinson, Mountain View, CA, USA).
VIII. Determination of Nitric Oxide
Peritoneal excluded macrophages were obtained
from mice(29) and incubated in RPMI 1640 medium in the
presence and absence of LPS (2 μg/mL) plus IFN-γ (10
U/mL), respectively. NO was determined by measuring
the accumulation of nitrite, a stable end product, in the
culture supernatant according to the Griess reaction (30).
Equal volumes of culture supernatant or serum were
mixed with Griess reagent and left over for 10 min at room
temperature. The optical density (OD) was measured with
a microplate reader (BIO-RAD, model 3550, USA) at 540
nm and the nitrite concentration in medium was calculated
using sodium nitrite as a standard.
IX. Cytokine Assay
Spleen cells (5 × 10 6 ) were incubated with and
without 5 μg/mL ConA in 24-well plates for 48 hr.
The culture supernatants were collected and stored at
-80°C prior to the analysis of enzyme-linked
immunosorbent assay (ELISA) (PharMingen, San Diego,
CA, USA) as described earlier(28). Briefly, 96-well plates
were coated with monoclonal antibody with specificity
for IL-2, IFN-γ, IL-4, or IL-10 and incubated overnight at
4°C, washed with 0.05% Tween 20 in PBS and blocked by
RPMI 1640 supplement with 10% FCS for 1 hr at room
temperature (RT). Serially diluted culture supernatants and
standards prepared from recombinant mouse IL-2, IFN-γ,
IL-4, and IL-10 separately (PharMingen, San Diego, CA,
USA) were added for 2 hr at RT. The wells of the plates
were washed and biotin-conjugated rat anti-mouse IL-2,
IFN-γ, IL-4, or IL-10 was added for another 1 hr at RT.
After proper washing, avidin-horseradish peroxidase was

added and incubated for 1 hr at RT. After aspirating and
washing, substrate (tetramethylbenzidine and hydrogen
peroxide) was added for 30 min at RT in the dark. The
optical density (OD) was measured with a microplate reader
(BIO-RAD, model 3550, USA) at 450 nm. The detection
sensitivities of IL-2, IFN-γ, IL-4, and IL-10 were 3.13 pg/
mL, 31.3 pg/mL, 7.8 pg/mL, and 31.3 pg/mL, respectively.
X. Statistical Analysis
All data are expressed as mean ± SD. Statistical
analysis was performed using one-way ANOVA followed
by Dunnetts post-hoc test, and the significant difference
was set at *p < 0.05; **p < 0.01.

Results
I. Effect of CGP Coadministration on the Tissue Distribution
of CsA
In order to investigate the in vivo interaction of CGP
and CsA, we used the optimal dose of CsA 10 mg/kg as
described in our previous study(31). The recoveries of CsA
from liver, kidney and spleen were 104.8 ± 3.21, 90.7 ± 2.16
and 103.7 ± 1.28% for the concentrations of 100.0, 200.0
and 500.0 ng/mL, respectively. After giving CsA with
different doses of CGP to mice, the concentrations of CsA
in blood, liver, kidney and spleen indicated that CGP dose
dependently decreased the levels of CsA in blood, liver,
kidney and spleen (Figure 1, Groups B~E). At the dose
of 3 g/kg CGP (Group E), the most profound reduction
of CsA concentration was found in spleen (51%), and the
least reduction in blood (37%), and the moderate decrease
in liver and kidney (about 45%).
II. Effect of CGP Coadministration on the Phagocytic
Activity in Blood
To f u r t h e r m e a s u r e t h a t t h e e f f e c t o f C G P
coadministration on the phagocytic activity, blood samples
were obtained from rats in Groups A~H and analyzed by a
Phagotest® kit. The phagocytic activities in the peripheral
blood were found comparable among groups of mice
before experiment. After two weeks of treatment, Group B
receiving CsA alone showed significantly lower phagocyte
activities in the peripheral blood than Group A, a control
group (Figure 2), whereas Groups C~E coadministered CGP
with CsA showed significantly higher phagocytic activity
than Group B. In addition, Groups F~H receiving CGP only
showed comparable phagocytic activity as Group A.
III. Effect of CGP Coadministration on the Function of
Peritoneal Macrophages
The function of peritoneal macrophages by
monitoring the secreted levels of nitric oxide (NO) under

169
Journal of Food and Drug Analysis, Vol. 14, No. 2, 2006
Table 1. The percentage of immune cells in spleen after various treatment
CD3

CD4

CD8

CD19

A
B

Negative control
CsA alone

53.28 ± 1.15
47.24 ± 2.63#

34.13 ± 2.25
30.39 ± 1.35#

18.22 ± 1.25
14.57 ± 1.56#

43.33 ± 2.35
49.16 ± 3.53#

Group

C

CsA + 1 g/kg CGP

52.32 ± 1.36*

36.61 ± 1.05*

15.61 ± 1.17

44.83 ± 3.36*

D

CsA + 2 g/kg CGP

52.18 ± 2.73*

36.97 ± 2.22*

16.76 ± 2.42

45.96 ± 2.78*

E

CsA + 3 g/kg CGP

52.51 ± 2.25*

36.74 ± 2.36*

16.27 ± 2.24

45.16 ± 3.05*

F

1 g/kg CGP alone

54.36 ± 3.62

36.84 ± 2.46

18.32 ± 1.66

43.78 ± 3.27

G
H

2 g/kg CGP alone
3 g/kg CGP alone

54.78 ± 3.44
54.62 ± 3.64

36.07 ± 2.27
36.36 ± 2.47

18.82 ± 2.62
18.86 ± 2.24

41.96 ± 3.56
40.16 ± 2.85

#

represents p < 0.05 compared to group A.
* represents p < 0.05 compared to group B.
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Figure 1. The concentrations of CsA in blood and various tissues. One hundred micro liter of blood, 1×107 spleen cells, 100 mg of liver
or kidney were homogenized in 100 μL of PBS after dosing different combinations of CsA and CGP to mice for two weeks. The CsA
concentration was measured by using a CsA kit (Abbott, Abbott Park, IL, USA) and expressed as ng/mL. Statistically compared with Group B:
*p < 0.05; **p < 0.01.

LPS/IFN-γ stimulation demonstrated that treatment with
CsA alone (Figure 3, Group B) significantly decreased NO
production. However, coadministration of various doses
of CGP with CsA significantly restored the decreased
NO production in a dose-dependent manner (Figure 3,
Groups C~E). In addition, treatments with various doses
of CGP alone (Groups F~H) showed no significant effects
compared to Group A.

IV. Effect of CGP Coadministration on the Population and
Function of Immune Cells in Spleen
The populations of total T cells (CD3+ cells), including
CD4 helper T cells, CD8+ cytotoxic T cells, and CD19+
B cells in spleen are shown in Table 1, indicating that
CsA significantly decreased the percentage of total T
cells in spleen (p < 0.05), especially CD8+ T cells to the
greatest extent, with a concomitant increase of CD19+ B
+
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Phagocytosis (%)

35
30

*
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**
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23.7

25.16

#
17.9
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0
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Figure 2. Effect of different combinations of CsA and CGP on
phagocyte activity of macrophages in vivo. The percentage of
phagocytes which have ingested bacteria was monitored by using
a FACscan flow cytometer (Becton Dickinson), and calculated by
the percentage of phagocytes which have ingested FITC-labeled
E. coli bacteria at 37°C minus the percentage of phagocytes which
have ingested FITC-labeled E. coli bacteria on ice. The data were
expressed as mean ± SD. Each group contains 8 mice. Statistically
compared with Group B: *p < 0.05; **p < 0.01 and compared with
Group A: # p < 0.05.

cells (p < 0.05). Coadministration of CGP (Groups C~E)
significantly restored the percentage of CD4+ T cells (p <
0.05). In contrast, administration of CGP alone resulted
in no significant change on the percentages of total T cells
and B cells (Table 1, Groups F~H). Further comparison
of cytokine levels secreted by ConA-stimulated spleen
cells indicated that T helper type 1 (Th1) cytokines, IL-2
and IFN-γ were markedly decreased after treatment with
CsA alone. However, coadministration with various doses
of CGP resulted in significant increase of Th1 cytokines
(Figure 4, Groups C~E compared to Group B, p < 0.05). In
addition, no significant difference was observed between
Group A and each group receiving CGP alone (Groups
F~H), indicating CGP treatment alone exerted no effect on
Th1 response. The results indicated that coadministration
with CGP reversed the effect of CsA on Th1 cytokine
production. However, no significant difference for Th2 type
cytokines, IL-4 and IL-10 was found among eight groups.

Discussion
This first report of the effect of CGP coadministration
on the concentrations of CsA in blood, kidney, liver
and spleen indicated that CGP significantly decreased
the in vivo concentrations of CsA in mice. However,
a previous pig study reported that the blood CsA level
after coadministration of single dose of CGP decoction
was higher than that after giving single dose of CsA
alone (24) . This discrepancy might be due to species
difference between pigs and mice or different dosage
regimen. Nevertheless, the influences in both species were
significant.
Previous studies have reported that, both in human
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Figure 3. The level of nitric oxide produced by peritoneal
macrophages. Murine peritoneal macrophages were added with LPS
(2 μg/mL) plus IFN-γ (10 U/mL) and supernatants were collected 48
hr after the initiation of the cultures to determine the amount of NO
by the method of Griess. Groups F~H were given CGP alone at 1, 2
and 3 g/kg, respectively. The data were expressed as the mean ± SD.
Statistically compared with Group B: *p < 0.05 and compared with
Group A: #p < 0.05.

and mice, CsA and calcineurin inhibition peaked at 1
hr after dosing and had higher concentration in spleen
and kidney than in blood (25). The mechanisms of CsA
toxicity had been reviewed(32) and include elements such
as vasoconstriction and interstitial fibrosis. The high
concentration of CsA in kidney and liver might probably
account for the serious nephrotoxic and hepatotoxic
side effects. Our results showed that CsA levels in
blood, spleen, liver and kidney were decreased by the
coadministration of CGP dose-dependently (Figure 1).
This indicated that CGP significantly decreased the
bioavailability of CsA, implying that CGP might decrease
the efficacy of CsA.
Traditional therapeutic monitoring is based on the
blood level of CsA. In the case of sirolimus, a novel
immunosuppressive drug, previous studies had shown that
the coadministration of sirolimus with CsA resulted in an
increase of CsA levels by 2-3 folds (33,34) and increased
the inhibition of lymphocyte function (35). In addition,
many studies indicated that St. John’s wort interacted with
CsA pharmacokinetically, leading significant decrease of
CsA exposure and resulted in acute rejection of transplant
organs(20-22,36). From pharmacokinetic point of view, the
CGP-CsA interaction might result in graft rejection as St.
John’s wort.-CsA interaction for organ transplant patients.
Previous report indicated that CsA reduced the
levels of NO and cyclooxygenase-2 produced by LPSactivated RAW264.7 cells (37). Our results showed that
coadministration of CGP significantly restored the NO
production suppressed by CsA. In addition to the reduced
activity of activated macrophages, we demonstrated that
CsA also decreased the percentage of CD4+ and CD8+ T
cells with a concomitant increase of CD19+ B cells (Table
1). Meanwhile, CsA was known to cause significant
decrease of Th1 type cytokines, IL-2 and IL-12, as well as
to inhibit IFN-γ from dendritic cells (DCs)(38). Moreover,
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Figure 4. The levels of cytokines secreted from ConA-stimulated spleen cells. Spleen cells (5×106) were incubated with and without 5 μg/mL
ConA in 24-well plates for 48 hr. The culture supernatants were collected and analyzed using a sandwich-ELISA as described in Methods. The
data were expressed as mean ± SD. Statistically compared with Group B: *p < 0.05 and compared with Group A: # p < 0.05.

CsA reduced co-stimulatory molecule expression and
further altered the antigen presenting function of DCs
for T cell activation (39) . In our study, IL-2 and IFN-γ
were markedly inhibited by CsA. However, when 3 g/kg
CGP was coadministered with CsA, the production of
Th1 type cytokines was significantly enhanced in ConAstimulated spleen cells. These pharmacodynamic effects
should be resulted from the CGP-CsA pharmacokinetic
interaction which showed a marked decrease of in vivo
CsA concentration.
Previous studies suggested that grapefruit juice
inhibited the intestine CYP3A4, but naringin, narirutin
and naringenin were not the major agents responsible for
the grapefruit juice-CsA interactions(40,41). A recent report
indicated that inhibition of P-gp was proposed to be a more
important mechanism for enhanced CsA absorption than
for inhibition of CYP 3A4 (42). Whether CGP elevated
CYP 3A4 or/and P-gp activity or increased the elimination
of CsA to result in significant decrease of CsA exposure
in mice awaits further studies and the causative agents in
CGP decoction remain to be clarified.
In conclusion, coadministration of CGP significantly
decreased the systemic exposure of CsA and resulted in
higher macrophage and Th1 type activities than giving
CsA alone in mice. The pharmacodynamic effect of CsA
was diminished by the pharmacokinetic interaction caused

by coadministration of CGP. Therefore, the combined use
of CGP with CsA requires close monitoring clinically.
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